Recommended Readings: Jos Jonkers, Ph.D., March 20

Friday Lecture Series
Friday, March 20, 2015
3:45 p.m., Caspary Auditorium

Jos Jonkers, Ph.D.
Head, Division of Molecular Pathology,
Netherlands Cancer Institute

Unraveling Therapy Response and Resistance in Mouse Models of Human Breast Cancer

Recommended Readings

Empirical Articles

Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., … & Jonkers, J. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology, 17(6), 688-695. doi:10.1038/nsmb.1831.

Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genetics, 29(4), 418-425. doi:10.1038/ng747

Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., … & Jonkers, J. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences, 104(29), 12111-12116. doi:10.1073/pnas.0702969104

Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O., Zander, S. A., … & Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences, 105(44), 17079-17084. doi:10.1073/pnas.0806092105

Review Papers

Bouwman, P., & Jonkers, J. (2014). Molecular Pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors?. Clinical Cancer Research, 20(3), 540-547. doi:10.1158/1078-0432.CCR-13-0225

Klarenbeek, S., van Miltenburg, M. H., & Jonkers, J. (2013). Genetically engineered mouse models of PI3K signaling in breast cancer. Molecular Oncology, 7(2), 146-164. doi:10.1016/j.molonc.2013.02.003